Weight change, genetics and antiepileptic drugs

Expert Review of Clinical Pharmacology

Volumn 7, Issue 1, 2014, Pages 43-51

  Chukwu, Joseph ^a,c   Delanty, Norman ^b,c   Webb, David ^a   Cavalleri, Gianpiero L ^c  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

epilepsy; genetics; obesity; pregabalin; sequencing; valproate; vigabatrin; weight

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ADIPONECTIN; ANTICONVULSIVE AGENT; ANTIOBESITY AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; GHRELIN; INSULIN; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; LEPTIN; MELANOCORTIN 4 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PERAMPANEL; PLACEBO; PREGABALIN; PROOPIOMELANOCORTIN; RETIGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADIPOCYTE; ALTERNATIVE MEDICINE; ANTICONVULSANT THERAPY; BODY WEIGHT; DNA SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPILEPSY; FOCAL EPILEPSY; GABAERGIC TRANSMISSION; GENE EXPRESSION; GENE FREQUENCY; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INSULIN BLOOD LEVEL; LENNOX GASTAUT SYNDROME; LIPID METABOLISM; MEDICATION COMPLIANCE; MOLECULAR BIOLOGY; NONHUMAN; OBESITY; PATHOGENESIS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; ANTICONVULSANTS; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICATION ADHERENCE; OBESITY; SEQUENCE ANALYSIS, DNA; VALPROIC ACID; VIGABATRIN; WEIGHT GAIN;

EID: 84893044473     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.857599     Document Type: Review

References (125)

1. Passani M, Blandina P, Torrealba F. Histamine H3 receptor and eating behavior. J. Pharmacol. Exp. Ther. 336, 24-29 (2011
2. Cabrera J, Emir B, Dills D, Murphy T, Whalen E, Clair A. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr. Med. Res. Opin. 28(6), 1027-1037 (2012
3. Stunkard A, Foch Tt, Hrubec Z. A twin study of human obesity. JAMA 256(1), 51-54. (1986
4. Fabsitz R, Sholinsky P, Carmelli D. Genetic influences on adult weight gain and maximum body mass index in male twins. Am. J. Epidemiol. 140(8), 711-720 (1994
5. Yeo GSH, Farooqi IS, Aminian S, Halsall D, Stanhope RG, O'rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat. Genet. 20(2), 111-112 (1998
6. Sohn J, Harris Le, Berglund Ed. et al. Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons. Cell 152(3), 612-619 (2013
7. Wangensteen T, Undlien D, Tonstad S, Retterstol L. [Genetic causes of obesity]. Tidsskr. Nor. Laegeforen. 125(22), 3090-3093 (2005
8. Korner J, Aronne L. Pharmacological approaches to weight reduction: Therapeutic targets. J. Clin. Endocrinol. Metab. 89(6), 2616-2621 (2004
9. Loos R. The genetic epidemiology of melanocortin 4 receptor variants. Eur. J. Pharmacol. 660(1), 156-164 (2011
10. Paz-Filho G, Wong M, Licinio J. Ten years of leptin replacement therapy. Obes. Rev. 12(5), e315-e323 (2011
11. Farooqi S, O'rahilly S. The genetics of obesity in humans. Endocr. Rev. 27(7), 710-718 (2006
12. Speliotes E, Willer C, Berndt S, Monda K, Thorleifsson G, Jackson A. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42(11), 937-948. (2010
13. Ben-Menachem E. Weight issues for people with epilepsy-A review. Epilepsia 48(Suppl. 9), 42-45 (2007
14. Hamed S. Leptin and Insulin homeostasis in epilepsy: Relation to weight adverse conditions. Epilepsy Res. 75, 1-9 (2007
15. Nakken KO. Physical exercise in outpatients with epilepsy. Epilepsia 40(5), 643-651 (1999
16. Ablah E, Haug A, Konda K. et al. Exercise and epilepsy: A survey of Midwest epilepsy patients. Epilepsy Behav. 14(1), 162-166 (2009
17. Wong J, Wirrell E. Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy. Epilepsia 47(3), 631-639 (2006
18. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb. Exp. Pharmacol. 209, 433-466 (2012
19. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Timely Top. Med. Cardiovasc. Dis. 9, E31 (2005
20. Mctigue KM, Hess R, Ziouras J. Obesity in older adults: A systematic review of the evidence for diagnosis and treatment. Obesity (Silver Spring) 14(9), 1485-1497 (2006
21. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin. Neuropharmacol. 30(4), 230-240 (2007
22. Biton V. Effect of antiepileptic drugs on bodyweight: Overview and clinical implications for the treatment of epilepsy. CNS Drugs 17(11), 781-791 (2003
23. Sheth R. Metabolic concerns associated with antiepileptic medications. Neurology 63 (10 Suppl. 4), S24-S29 (2004
24. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr. Neurol. 22, 361-364 (2000
25. Corman C, Leung N, Guberman A. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can. J. Neurol. Sci. 24, 240-244 (1997
26. Verrotti A, La Torre R, Trotta D, Mohn A, Chiarelli F. Valproate-induced insulin resistance and obesity in children. Horm. Res. 71(3), 125-131 (2009
27. Elaine C, Wirrell M. Valproic acid-Associated weight gain in older children and teens with epilepsy. Pediatr. Neurol. 28, 126-129 (2003
28. Mikkonen K, Knip M, Pakarinen A, Lanning P, Isojarvi J, Vainionpaa L. Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation. Epilepsia 46, 1114-1120 (2005
29. Egger J, Brett E. Effects of sodium valproate in 100 children with special reference to weight. Br. Med. J. 283(6291), 577-581 (1981
30. El-Khayat HA, Shatla HM, Ali GK, Abdulgani MO, Tomoum HY, Attya Ha. Physical and hormonal profile of male sexual development in epilepsy. Epilepsia 44, 447-452 (2003
31. Isojarvi J, Laatikainen T, Pakarinen A, Juntunen K, Myllyla V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New Engl. J. Med. 329, 1383-1388 (1993
32. Wirrell EC. Valproic acid-Associated weight gain in older children and teens with epilepsy. Pediatr. Neurol. 28(2), 126-129 (2003
33. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 53, 230-232 (1999
34. Caksen H, Deda G, Berberoglu M. Does long-Term use of valproate cause weight gain in pre-pubertal epileptic children? Int. J. Neurosci. 112, 1183-1189 (2002
35. El-Khayat H, Abd El-Basset F, Tomoum H. et al. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsy Behav. 45, 1106-1115 (2004
36. Prabhakar S, Sahota P, Kharbanda P. et al. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: A prospective study. Epilepsia 48, 1371-1377 (2007
37. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol. Scand. 70(2), 65-69 (1984
38. Pylvanen V, Knip M, Pakarinen AJ. et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 60(4), 571-574 (2003
39. El-Khatib F, Rauchenzauner M, Lechleitner M. et al. Valproate, weight gain and carbohydrate craving: A gender study. Seizure 16, 226-232 (2007
40. Luef G, Abraham I, Trinka E. et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res. 48(1-2), 91-102 (2002
41. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI. Serum insulin and leptin levels in valproate-Associated obesity. Epilepsia 43(5), 514-517 (2002
42. Verrotti A, La Torre R, Trotta D, Mohn A, Chiarelli F. Valproate-induced insulin resistance and obesity in children. Horm. Res. 71(3), 125-131 (2009
43. Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Characterization of insulin secretion in Valproate-Treated patients with epilepsy. Epilepsia 47(9), 1460-1464 (2006
44. Vorbrodt A, Dobrogowska D, Kozlowski P, Rabe A, Tarnawski M, Lee M. Immunogold study of effects of prenatal exposure to lipopolysaccharide and/or valproic acid on the rat blood-brain barrier vessels. J. Neurocytol. 34(6), 435-446 (2005
45. Aydin K, Serdaroglu A, Okuyaz C, Bideci A, Gucuyener K. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J. Child Neurol. 20, 848-851 (2005
46. Hamed S, Fida N, Hamed E. States of serum leptin and insulin in children with epilepsy: Risk predictors of weight gain. Eur. J. Paediatr. Neurol. 13(3), 261-268 (2009
47. Mania M, Kasradze S, Okujava N. Valproic Acid related metabolic syndrome in patients with epilepsy. Georgian Med. News (194), 43-47 (2011
48. Cansu A, Serdaroglu A, Camurdan O, Hirfanoglu T, Cinaz P. Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate. Horm. Res. Paediatr. 76(1), 65-71 (2011
49. Rauchenzauner M, Haberlandt E, Scholl-Burgi S. et al. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res. 80, 142-149 (2008
50. Grosso S, Luisi S, Mostardini R. et al. Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy. Neuroendocrinol. 93(3), 159-164 (2011
51. Hamed S, Fida N, Hamed E. States of serum leptin and insulin in children with epilepsy: Risk predictors of weight gain. Eur. J. Paediatr. Neurol. 13(3), 261-268 (2009
52. Gungor G, Yucel A, Akinci A, Tabel Y, Ozerol IH, Yologlu S. The role of ghrelin in weight gain and growth in epileptic children using valproate. J. Child Neurol. 22, 1384-1388 (2007
53. Qiao L, Schaack J, Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 147(2), 865-874 (2006
54. Lee E, Warmann G, Dhir R, Ahima R. Metabolic dysfunction associated with adiponectin deficiency enhances kainic acid-induced seizure severity. J. Neurosci. 31(40), 14361-14366 (2011
55. Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65, 1808-1809 (2005
56. Martin CK, Han H, Anton SD, Greenway FL, Smith SR. Effect of valproic acid on body weight, food intake, physical activity and hormones: Results of a randomized controlled trial. J. Psychopharmacol. 23(7), 814-825 (2009
57. Brill J, Lee M, Zhao S, Fernald RD, Huguenard Jr. Chronic valproic acid treatment triggers increased neuropeptide y expression and signaling in rat nucleus reticularis thalami. J. Neurosci. 26(25), 6813-6822 (2006
58. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56, 172-177 (2001
59. Jallon P, Picard F. Bodyweight gain and anticonvulsants: A comparative review. Drug Saf. 23(13), 969-978 (2001
60. Tokgoz H, Aydin K, Oran B, Kiyici A. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv. Syst. 28(7), 1049-1053 (2012
61. Stephen LJ, Parker P, Kelly K, Wilson EA, Leach V, Brodie MJ. Adjunctive pregabalin for uncontrolled partial-onset seizures: Findings from a prospective audit. Acta Neurol. Scand. 124(2), 142-145 (2011
62. Safety EOOD. Drug safety evaluation of pregabalin. Expert Opin. Drug Safety 11(3), 487-502 (2012
63. Lyrica® (pregabalin) capsule. Parke-Davis Div of Pfizer Inc., NY, USA (2006
64. Arroyo S, Anhut H, Kugler AR. et al. Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45(1), 20-27 (2004
65. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64(3), 475-480 (2005
66. Ben-Menachem E, Mette Axelsen M, Johanson E, Stagge A, Smith U. Predictors of weight loss in adults withtopiramate-Treated epilepsy. Obes. Res. 11(3), 556-556 (2003
67. Gilliam FG, Veloso F, Bomhof MA. et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 60(2), 196-202 (2003
68. Arroyo S, Dodson W, Privitera M. et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol. Scand. 112(4), 214-222 (2005
69. Privitera M, Brodie M, Mattson R. et al. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 107, 165-175 (2003
70. Reife R, Pledge G, Wu S. Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adult. Epilepsia 41(Suppl. 1), S66-S71 (2000
71. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: A review. Epilepsy Res. 95(3), 189-199. (2011
72. Reiter E, Feucht M, Hauser E, Freilinger M, Seidl R. Changes in body mass index during long-Term topiramate therapy in paediatric epilepsy patients-A retrospective analysis. Seizure 13(7), 491-493 (2004
73. Sachdeo R, Glauser T, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 52, 1882-1887 (1999
74. Shi R, Wang Kl, Li QH. et al. Changes of body weight and galanin in epileptic children treated with topiramate. Zhonghua Er Ke Za Zhi. 45(3), 199-202 (2007
75. Lalonde J, Samson P, Poulin S, Deshaies Y, Richard D. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol. Behav. 80(4), 415-420 (2004
76. Shi RF, Wang KL, Li QH. et al. [Changes of body weight and galanin in epileptic children treated with topiramate]. Zhonghua er ke za zhi 45(3), 199-202 (2007
77. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 8(9), 656-663 (2000
78. Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. Relat. Metab. Disord. 26(3), 344-353 (2002
79. Astrup A, Caterson I, Zelissen P. et al. Topiramate: Long-Term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 12(10), 1658-1669 (2004
80. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: Alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 16(10), 967-975 (2000
81. Tremblay A, Chaput JP, Berube-Parent S. et al. The effect of topiramate on energy balance in obese men: A 6-month doubleblind randomized placebo-controlled study with a 6-month open-label extension. Eur. J. Clin. Pharmacol. 63(2), 123-134 (2007
82. Schütt M, Brinkhoff J, Drenckhan M, Lehnert H, Sommer C. Weight reducing and metabolic effects of topiramate in patients with migraine -An observational study. Exp. Clin. Endocrinol. Diabetes 118(7), 449-452 (2010
83. Genc B, Dogan E, Dogan U, Genc E. Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment. J. Clin. Neurosci. 17(10), 1256-1259 (2010
84. Davalli A, Perego C, Folli F, Bosi E. Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. Acta Diabetol. 49(1), 75-79 (2012
85. Sleddering M, Snel M, Streefland T, Pijl H, Jazet I. Short-Term topiramate treatment does not improve insulin sensitivity or secretion in obese insulin-resistant women. Eur. J. Endocrinol. 167(6), 839-845 (2012
86. Khanna V, Arumugam S, Roy S, Mittra S, Bansal V. Topiramate and type 2 diabetes: An old wine in a new bottle. Expert Opin. Ther. Targets 12(1), 81-90 (2008
87. Wellmer J, Wellmer S, Bauer J. The impact of zonisamide on Weight. A clinical study in n103 patients with epilepsy. Acta Neurol. Scand. 119(4), 233-238 (2009
88. Yang J, Lee M, Joe S, Jung I, Kim S. Zonisamide-induced weight loss in schizophrenia: Case series. . Clin. Neuropharmacol. 33(2), 104-106 (2010
89. Gadde K, Kopping M, Wagner HN, Yonish G, Allison D, Bray G. Zonisamide for weight reduction in obese adults: A 1-year randomized controlled trial. Arch. Intern. Med. 172(20), 1557-1564 (2012
90. Kim DW, Yoo MW, Park KS. Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. Epilepsy Behav. 23(4), 497-499 (2012
91. Gadde KM, Allison DB, Ryan DH. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet 377(9774), 1341-1352 (2011
92. Hogan RE, Bertrand ME, Deaton RL, Sommerville KW. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res. 41(1), 23-28 (2000
93. Turpin E, Muscat A, Vatier C. et al. Carbamazepine directly inhibits adipocyte differentiation through activation of the ERK 1/2 pathway. Br. J. Pharmacol. 168(1), 139-150 (2013
94. Baulac M, Cavalcanti D, Semah F, Arzimanoglou A, Portal JJ. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: An open, observational study. The French Gabapentin Collaborative Group. Seizure 7(1), 55-62 (1998
95. Detoledo JC, Toledo C, Decerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther. Drug Monit. 19(4), 394-396 (1997
96. Bergen DC, Ristanovic RK, Waicosky K, Kanner A, Hoeppner TJ. Weight loss in patients taking felbamate. Clin. Neuropharmacol. 18(1), 23-27 (1995
97. Cilio MR, Kartashov AI, Vigevano F. The long-Term use of felbamate in children with severe refractory epilepsy. Epilepsy Res. 47(1-2), 1-7 (2001
98. Sisodiya S, Marini C. Genetics of antiepileptic drug resistance. Curr. Opin. Neurol. 22(2), 150-156 (2009
99. Cohen AL, Soldi R, Zhang H. et al. A pharmacogenomic method for individualized prediction of drug sensitivity. Mol. Syst. Biol. 7, 513 (2011
100. López M, Dorado P, Monroy N. et al. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabol. Drug Interact. 26(1), 5-12 (2011
101. Cavalleri G, Mccormack M, Alhusaini S, Chaila E, Delanty N. Pharmacogenomics and epilepsy: The road ahead. Pharmacogenomics 12(10), 1429-1447 (2011
102. Berkovic S, Cossette P, Delanty N. et al.; Epi4K Consortium. Epi4K: Gene discovery in 4,000 genomes. Epilepsia 53(8), 1457-1467 (2012
103. Egger J, Brett E. Effects of sodium valproate in 100 children with special reference to weight. BMJ 283, 577-580 (1981
104. Novak G, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. J. Child Neurol. 14, 490-495 (1999
105. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology 67(10), 1792-1800 (2006
106. Arroyo S, Anhut H, Kugler AR. et al. Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45(1), 20-27 (2004
107. Biton V, Montouris GD, Ritter F. et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC study group. Neurology 52(7), 1330-1337 (1999
108. Gadde KM, Kopping MF, Wagner HR 2nd, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: A 1-year randomized controlled trial. Arch. Intern. Med. 172(20), 1557-1564 (2012
109. Breum L, Astrup A, Gram L. et al. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism 41(6), 666-670 (1992
110. Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus valproate monotherapy-Associated weight change in adolescents with epilepsy: Results from a post hoc analysis of a randomized, double-blind clinical trial. J. Child Neurol. 18(2), 133-139 (2003
111. Isojarvi JI, Rattya J, Myllyla VV. et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. 43(4), 446-451 (1998
112. Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J. Child Neurol. 17, 265-268 (2002
113. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin. Endocrinol. 39(1), 1-16 (1993
114. Verrotti A, Basciani F, Morresi S, De Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 53(1), 230-232 (1999
115. Reiterer EE, Sudi KM, Mayer A. et al. Changes in leptin, insulin and body composition in obese children during a weight reduction program. J. Pediatr. Endocrinol. Metab. 12(6), 853-862 (1999
116. Considine RV. Human leptin: An adipocyte hormone with weight-regulatory and endocrine functions. Semin. Vasc. Med. 5(1), 15-24 (2005
117. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 148(3), 293-300 (2003
118. Gil-Campos M, Canete R, Gil A. Hormones regulating lipid metabolism and plasma lipids in childhood obesity. Int. J. Obes. Relat. Metab. Disord. 28 (Suppl. 3), S75-S80 (2004
119. Martin B, Dotson CD, Shin YK. et al. Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann. NY Acad. Sci. 1170, 98-101 (2009
120. Fleury C, Neverova M, Collins S. et al. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 15(3), 269-272 (1997
121. Mcelroy SL, Suppes T, Keck PE. et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatr. 47(12), 1025-1033 (2000
122. Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial. Schizophr. Res. 118(1-3), 218-223 (2010
123. Supuran C. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov 7, 168-181 (2008
124. Vitale R, Pedone C, Amodeo P. et al. Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA. Bioorg. Med. Chem. 15, 4152-4158 (2007
125. Supuran C. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Pat. 13, 1545-1550 (2003